.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech want to detail on the Nasdaq under the icon "BIOA," depending on to files filed with the Stocks and also Substitution Commission. The company has actually certainly not publicly shared an expected financial amount for the offering.The clinical-stage business proclaims lead applicant azelaprag, an orally delivered small particle slated to get into phase 2 testing in combination with semaglutide-- sold by Novo Nordisk under brand Wegovy for fat loss-- in the initial one-half of next year. Semaglutide is actually likewise offered as Ozempic and Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is designed to blend effectively along with GLP-1 medicines, improving weight management while protecting muscle mass. The investigational medication was located to be well-tolerated amongst 265 individuals across 8 phase 1 tests, depending on to BioAge.Recently, BioAge amassed the help of Lilly to operate a test combining azelaprag along with the Large Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes as Mounjaro and Zepbound for effective weight loss. The partners are actually presently conducting a phase 2 trial of azelaprag and also tirzepatide, with topline outcomes assumed in the third quarter of 2025.The biotech is also organizing an insulin sensitivity proof-of-concept trial determining azelaprag as a monotherapy in the very first half of following year to sustain prospective sign development. Moreover, the firm considers to inquire the FDA for consent in the 2nd half of 2025 to release individual testing for an NLRP3 inhibitor targeting metabolic conditions as well as neuroinflammation.BioAge's expected relocate to the public market adheres to a minor uptick in intended biotech IPOs from Bicara Therapies as well as Zenas Biopharma. Zooming out, the latest IPO garden is a "combined image," along with top quality firms still debuting on the public markets, only in reduced numbers, according to PitchBook.